Direct-Haler A/S is a privately owned drug delivery company. The company is focused on research & development and out-licensing of innovative and world-wide patented drug delivery device technology, and novel therapeutic approaches involving pulmonary and nasal delivery.

The innovation philosophy behind the DirectHaler™ technologies and novel therapeutic approaches, is to broaden the development scope not only to focus on the unmet needs of the patient, but also the unmet needs of GPs, therapeutic specialists, instruction nurses, pharmacies and sales representatives and supply chain management.

Our device technologies enable pharmaceutical – and biotechnology companies to obtain maximum flexibility in the supply chain: If wanted, then our licensees can acquire right to use local component suppliers or establish own manufacturing, filling and packing of DirectHaler™ devices.

Patent protected technologies
Direct-Haler A/S is with background in own R&D, offering license to patents and intellectual property:

• DirectHaler™ Pulmonary (issued patents in 41 countries)
• DirectHaler™ Nasal (issued patents in 42 countries)
• Device customizations (patents pending)
• DirectHaler™ Multiple route medication (patent pending)

Partnering outlook
We are seeking to out-license the DirectHaler™ technologies and the respiratory products in development.